Publicacións en colaboración con investigadores/as de Universitat Autònoma de Barcelona (101)

2024

  1. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 23-32

2023

  1. A Study of the Prevalence of Asthma in the General Population in Spain

    Open Respiratory Archives, Vol. 5, Núm. 2

  2. Burden of refractory and unexplained chronic cough on patients’ lives: a cohort study

    ERJ Open Research, Vol. 9, Núm. 5

  3. Disposition of Work-Related Asthma in a Spanish Asthma Cohort: Comparison of Asthma Severity Between Employed and Retired Workers

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 11, pp. 3407-3413.e1

  4. Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 281-288

  5. Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 223-231

  6. Impact of Air Pollution on Asthma: A Scoping Review

    Open Respiratory Archives, Vol. 5, Núm. 2

  7. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti–IL-5 Biologics: A Real-Life Study

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 1, pp. 37-44

  8. Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 294-296

  9. Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study

    Drugs, Vol. 83, Núm. 12, pp. 1111-1123

  10. Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma

    Frontiers in Pharmacology, Vol. 14

  11. Reply to “Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies”

    Journal of Investigational Allergology and Clinical Immunology

  12. Response to Monoclonal Antibodies in Asthma: Definitions, Potential Reasons for Failure, and Therapeutic Options for Suboptimal Response

    Journal of investigational allergology & clinical immunology, Vol. 33, Núm. 1, pp. 1-13

  13. Role of Different Health Care Professionals in the Management of Asthma Patients: The GEMA-FORUM IV Task Force

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 3, pp. 214-217

  14. The New ERS/ATS 2022 Bronchodilator Response Recommendation: Comparison With the Previous Version in an Asthma Cohort

    Archivos de Bronconeumologia, Vol. 59, Núm. 9, pp. 608-611

  15. Treatment Patterns of Monoclonal Antibodies in Patients With Severe Uncontrolled Asthma Treated by Pulmonologists in Spain

    Open Respiratory Archives, Vol. 5, Núm. 3

  16. Validation of the Asthma Impairment and Risk Questionnaire in Spain: A Useful Tool for Assessing Asthma Control in Adolescents and Adults

    Journal of Investigational Allergology and Clinical Immunology

  17. What's New in the 2022 Consensus for Severe Asthma in Adults

    Archivos de Bronconeumologia

2022

  1. A Polygenic Risk Score Based on a Cardioembolic Stroke Multitrait Analysis Improves a Clinical Prediction Model for This Stroke Subtype

    Frontiers in Cardiovascular Medicine, Vol. 9

  2. Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial

    European Respiratory Journal